Your browser doesn't support javascript.
loading
Quercetin-3-oleoyl derivatives as new GPR40 agonists: Molecular docking studies and functional evaluation.
Carullo, Gabriele; Perri, Mariarita; Manetti, Fabrizio; Aiello, Francesca; Caroleo, Maria Cristina; Cione, Erika.
Afiliação
  • Carullo G; Department of Pharmacy, Health and Nutritional Sciences, "Dipartimento di Eccellenza 2018-2022", University of Calabria, Edificio Polifunzionale, 87036 Rende, Italy.
  • Perri M; Department of Pharmacy, Health and Nutritional Sciences, "Dipartimento di Eccellenza 2018-2022", University of Calabria, Edificio Polifunzionale, 87036 Rende, Italy.
  • Manetti F; Department of Biotechnology, Chemistry and Pharmacy, "Dipartimento di Eccellenza 2018-2022", University of Siena, Via Aldo Moro, 2, 53100 Siena, Italy.
  • Aiello F; Department of Pharmacy, Health and Nutritional Sciences, "Dipartimento di Eccellenza 2018-2022", University of Calabria, Edificio Polifunzionale, 87036 Rende, Italy. Electronic address: francesca.aiello@unical.it.
  • Caroleo MC; Department of Pharmacy, Health and Nutritional Sciences, "Dipartimento di Eccellenza 2018-2022", University of Calabria, Edificio Polifunzionale, 87036 Rende, Italy.
  • Cione E; Department of Pharmacy, Health and Nutritional Sciences, "Dipartimento di Eccellenza 2018-2022", University of Calabria, Edificio Polifunzionale, 87036 Rende, Italy.
Bioorg Med Chem Lett ; 29(14): 1761-1764, 2019 07 15.
Article em En | MEDLINE | ID: mdl-31104992
ABSTRACT
The G-protein-coupled receptor 40 (GPR40) is an attractive molecular target for the treatment of type 2 diabetes mellitus. Previously, based on the natural oleic acid substrate, an exogenous ligand for this receptor, named AV1, was synthesized. In this context, here we validated the activity of AV1 as a full agonist, while the corresponding catechol analogue, named AV2, was investigated for the first time. The ligand-protein interaction between this new molecule and the receptor was highlighted in the lower portion of the GPR40 groove that generally accommodates DC260126. The functional assays performed have demonstrated that AV2 is a suitable GPR40 partial agonist, showing a therapeutic potential and representing a useful tool in the management of type 2 diabetes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quercetina / Simulação de Acoplamento Molecular Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quercetina / Simulação de Acoplamento Molecular Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article